Sacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms
Copyright © 2020 Elsevier Inc. All rights reserved..
OBJECTIVE: To assess the efficacy, safety, and outcomes of sacral nerve stimulation (SNS) for Parkinson's disease (PD) patients with overactive bladder symptoms.
METHODS: We retrospectively reviewed PD patients who underwent Stage I SNS. Demographics, urodynamic data, and baseline voiding function were analyzed. Efficacy and safety of treatment were determined by rate of progression to Stage II, explantation, and surgical revision. Long-term outcomes were assessed using voiding diaries and/or clinic notes.
RESULTS: Sixty percent (9/15) experienced ≥50% improvement in urinary parameters and proceeded to Stage II. There was no significant difference in age, body mass index, comorbidities, PD disease duration, or levodopa equivalent daily dose between successful and nonsuccessful Stage I patients. However, 100% of female patients experienced Stage I success compared to 44% of male PD patients (P = .04). Individuals with >12-month follow-up experienced an average reduction of 6 voids/day. No patients required revision or explantation of their device at latest clinic follow-up (22.2 ± 7.8 months). Higher maximal urethral closure pressures, detrusor pressure at maximum flow rate (PdetQmax), post-void residual volume, and mean bladder outlet obstruction index were observed in the Stage I trial failures.
CONCLUSION: At our institution, PD patients have a similar rate of progression to Stage II compared to the general population. SNS is an effective therapy that should be considered among the treatment options for PD patients with overactive bladder symptoms. Urodynamic parameters associated with obstruction may be predictive of SNS failure in PD patients and may help guide patient selection, however further studies are needed.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
Urology - 144(2020) vom: 15. Okt., Seite 99-105 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Greenberg, Daniel R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.02.2022 Date Revised 03.02.2022 published: Print-Electronic CommentIn: J Urol. 2021 Aug;206(2):482-485. - PMID 33983047 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.urology.2020.06.063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312582382 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312582382 | ||
| 003 | DE-627 | ||
| 005 | 20231225144724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urology.2020.06.063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312582382 | ||
| 035 | |a (NLM)32681915 | ||
| 035 | |a (PII)S0090-4295(20)30830-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Greenberg, Daniel R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2022 | ||
| 500 | |a Date Revised 03.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Urol. 2021 Aug;206(2):482-485. - PMID 33983047 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To assess the efficacy, safety, and outcomes of sacral nerve stimulation (SNS) for Parkinson's disease (PD) patients with overactive bladder symptoms | ||
| 520 | |a METHODS: We retrospectively reviewed PD patients who underwent Stage I SNS. Demographics, urodynamic data, and baseline voiding function were analyzed. Efficacy and safety of treatment were determined by rate of progression to Stage II, explantation, and surgical revision. Long-term outcomes were assessed using voiding diaries and/or clinic notes | ||
| 520 | |a RESULTS: Sixty percent (9/15) experienced ≥50% improvement in urinary parameters and proceeded to Stage II. There was no significant difference in age, body mass index, comorbidities, PD disease duration, or levodopa equivalent daily dose between successful and nonsuccessful Stage I patients. However, 100% of female patients experienced Stage I success compared to 44% of male PD patients (P = .04). Individuals with >12-month follow-up experienced an average reduction of 6 voids/day. No patients required revision or explantation of their device at latest clinic follow-up (22.2 ± 7.8 months). Higher maximal urethral closure pressures, detrusor pressure at maximum flow rate (PdetQmax), post-void residual volume, and mean bladder outlet obstruction index were observed in the Stage I trial failures | ||
| 520 | |a CONCLUSION: At our institution, PD patients have a similar rate of progression to Stage II compared to the general population. SNS is an effective therapy that should be considered among the treatment options for PD patients with overactive bladder symptoms. Urodynamic parameters associated with obstruction may be predictive of SNS failure in PD patients and may help guide patient selection, however further studies are needed | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Sohlberg, Ericka M |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chiyuan A |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Veronica E |e verfasserin |4 aut | |
| 700 | 1 | |a Comiter, Craig V |e verfasserin |4 aut | |
| 700 | 1 | |a Enemchukwu, Ekene A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urology |d 1973 |g 144(2020) vom: 15. Okt., Seite 99-105 |w (DE-627)NLM000023930 |x 1527-9995 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2020 |g day:15 |g month:10 |g pages:99-105 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.urology.2020.06.063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 144 |j 2020 |b 15 |c 10 |h 99-105 | ||